{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:34Z","timestamp":1789469134944,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease with limited treatment options. The COMMODORE 2 study demonstrated that the novel C5 inhibitor crovalimab had comparable safety and non-inferior efficacy to eculizumab. We evaluated the safety and efficacy of crovalimab compared with eculizumab in the Chinese subpopulation of the global COMMODORE 2 study. Adult patients with PNH without previous complement inhibitor therapy were randomized (2:1) to crovalimab or eculizumab for 24 weeks. The co-primary endpoints were the proportions of patients achieving hemolysis control from Weeks 5\u201325 and those with transfusion avoidance from baseline to Week 25. The secondary endpoints included the proportion of patients with breakthrough hemolysis and hemoglobin stabilization from baseline to Week 25 and the mean change from baseline in FACIT-Fatigue score at Week 25. Safety data were assessed from baseline to the clinical cut-off (16 November 2022). The demographic and baseline characteristics of the 81 patients included (eculizumab: 27; crovalimab: 54) were well-balanced. In the crovalimab and eculizumab arms, respectively, hemolysis control was achieved in 88.3% and 86.8%, transfusion avoidance in 72.2% and 74.1%, hemoglobin stabilization in 72.2% and 70.4%, and breakthrough hemolysis in 5.6% and 11.1%. The FACIT-Fatigue score improvement was greater with crovalimab. Adverse events (81.5% vs. 88.9%) and grade 3\u20135 adverse events (24.1% vs. 33.3%) were less frequent with crovalimab. Over 24 weeks, 91% of patients achieved complete terminal complement inhibition with crovalimab. Crovalimab demonstrated at least comparable treatment performance and acceptable safety in Chinese patients with PNH.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial registration<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>ClinicalTrials.gov identifier NCT04434092 (study registration was first posted on 16th June 2020).<\/jats:p>","DOI":"10.1007\/s00277-026-07129-3","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T08:34:18Z","timestamp":1781339658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-na\u00efve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study"],"prefix":"10.1007","volume":"105","author":[{"given":"Hongyan","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Appius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-5897","authenticated-orcid":false,"given":"Guangsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"7129_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13059","volume":"101","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Maciejewski J, Nishimura JI, Jain D, Weitz JI (2018) Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: expert consensus. Eur J Haematol 101:3\u201311. https:\/\/doi.org\/10.1111\/ejh.13059","journal-title":"Eur J Haematol"},{"key":"7129_CR2","unstructured":"General Office, National Health Commission (2019) China rare diseases diagnosis and treatment guide (2019 edition). Accessed 6 Mar 2025"},{"key":"7129_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-90-481-9485-8_22","volume":"686","author":"B Gulbis","year":"2010","unstructured":"Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surrall\u00e9s J, Castella M et al (2010) Epidemiology of rare anaemias in Europe. Adv Exp Med Biol 686:375\u2013396. https:\/\/doi.org\/10.1007\/978-90-481-9485-8_22","journal-title":"Adv Exp Med Biol"},{"key":"7129_CR4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Soci\u00e9 G, Szer J, Urbano-Ispizua A, Maciejewski JP et al (2014) Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 99:922\u2013929. https:\/\/doi.org\/10.3324\/haematol.2013.093161","journal-title":"Haematologica"},{"key":"7129_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/16078454.2021.2022849","volume":"27","author":"Y Du","year":"2022","unstructured":"Du Y, Yang Y, Yang C, Chen M, Han B (2022) Clinical characteristics of 512 eculizumab-na\u00efve paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study. Hematology 27:113\u2013121. https:\/\/doi.org\/10.1080\/16078454.2021.2022849","journal-title":"Hematology"},{"key":"7129_CR6","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, D\u00fchrsen U, Risitano AM, Schubert J, Luzzatto L et al (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:4123\u20134128. https:\/\/doi.org\/10.1182\/blood-2007-06-095646","journal-title":"Blood"},{"key":"7129_CR7","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3324\/haematol.2012.062828","volume":"97","author":"R Peffault de Latour","year":"2012","unstructured":"Peffault de Latour R, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S et al (2012) Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 97:1666\u20131673. https:\/\/doi.org\/10.3324\/haematol.2012.062828","journal-title":"Haematologica"},{"key":"7129_CR8","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1182\/blood.2019003812","volume":"113","author":"RA Brodsky","year":"2009","unstructured":"Brodsky RA (2009) How I treat paroxysmal nocturnal hemoglobinuria. Blood 113:6522\u20136527. https:\/\/doi.org\/10.1182\/blood.2019003812","journal-title":"Blood"},{"key":"7129_CR9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J et al (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840\u20131847. https:\/\/doi.org\/10.1182\/blood-2007-06-094136","journal-title":"Blood"},{"key":"7129_CR10","volume-title":"Paroxysmal nocturnal hemoglobinuria","author":"N Shah","year":"2023","unstructured":"Shah N, Bhatt H (2023) Paroxysmal nocturnal hemoglobinuria. StatPearls Publishing, Treasure Island (FL)"},{"key":"7129_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, R\u00f6th A, Elebute MO, Risitano AM, Schrezenmeier H et al (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162:62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347","journal-title":"Br J Haematol"},{"key":"7129_CR12","doi-asserted-by":"publisher","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M et al (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117:6786-6792. https:\/\/doi.org\/10.1182\/blood-2011-02-33399","DOI":"10.1182\/blood-2011-02-33399"},{"key":"7129_CR13","doi-asserted-by":"publisher","unstructured":"Brodsky RA, Peffault de Latour R, Rottinghaus ST, R\u00f6th A, Risitano AM, Weitz IC, et al (2021) Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica 106:230-237. https:\/\/doi.org\/10.3324\/haematol.2019.236877","DOI":"10.3324\/haematol.2019.236877"},{"key":"7129_CR14","doi-asserted-by":"publisher","unstructured":"14.\tLee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK et al (2013) Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol 97:749-757. https:\/\/doi.org\/10.1007\/s12185-013-1346-4","DOI":"10.1007\/s12185-013-1346-4"},{"key":"7129_CR15","unstructured":"ClinicalTrials.gov (2025) A phase III study evaluating the efficacy and safety of crovalimab versus eculizumab in participants with paroxysmal nocturnal hemoglobinuria (PNH) not previously treated with complement inhibitors. (COMMODORE 2). https:\/\/clinicaltrials.gov\/study\/NCT04434092?intr=crovalimab%20&rank=8 Accessed 6 March 2025"},{"key":"7129_CR16","doi-asserted-by":"publisher","first-page":"e72750f1","DOI":"10.1097\/01.HS9.0000967636.72750.f1","volume":"7","author":"A R\u00f6th","year":"2023","unstructured":"R\u00f6th A, He G, Brodsky A, Chai-Adisaksopha CC, Dumagay T, Demichelis R et al (2023) S181: The phase III, randomized COMMODORE 2 trial: results from a multicenter study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients na\u00efve to complement inhibitors. Hemasphere 7:e72750f1. https:\/\/doi.org\/10.1097\/01.HS9.0000967636.72750.f1","journal-title":"Hemasphere"},{"key":"7129_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Lee Lee LW, Pessoa V, Gualandro S, F\u00fcreder W et al (2019) Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133:530\u2013539. https:\/\/doi.org\/10.1182\/blood-2018-09-876136","journal-title":"Blood"},{"key":"7129_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzales-Fernandez FA et al (2019) Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133:540\u2013549. https:\/\/doi.org\/10.1182\/blood-2018-09-876805","journal-title":"Blood"},{"key":"7129_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1248\/bpb.b15-00703","volume":"39","author":"H Nakayama","year":"2016","unstructured":"Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T (2016) Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull 39:285\u2013288. https:\/\/doi.org\/10.1248\/bpb.b15-00703","journal-title":"Biol Pharm Bull"},{"key":"7129_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"R de Peffault","year":"2015","unstructured":"de Peffault R, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC et al (2015) Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 125:775\u2013783. https:\/\/doi.org\/10.1182\/blood-2014-03-560540","journal-title":"Blood"},{"key":"7129_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-023-02779-2","volume":"18","author":"S Adhikari","year":"2023","unstructured":"Adhikari S, Sapkota S, Shrestha S, Karki K, Shrestha A (2023) Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients. Orphanet J Rare Dis 18:172. https:\/\/doi.org\/10.1186\/s13023-023-02779-2","journal-title":"Orphanet J Rare Dis"},{"key":"7129_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","volume":"7","author":"T Fukuzawa","year":"2017","unstructured":"Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y et al (2017) Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep 7:1080. https:\/\/doi.org\/10.1038\/s41598-017-01087-7","journal-title":"Sci Rep"},{"key":"7129_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL et al (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639. https:\/\/doi.org\/10.1056\/NEJMoa1311084","journal-title":"N Engl J Med"},{"key":"7129_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1182\/blood.2019003399","volume":"135","author":"A R\u00f6th","year":"2020","unstructured":"R\u00f6th A, Nishimura JI, Nagy Z, Ga\u00e0l-Weisinger J, Panse J, Yoon SS et al (2020) The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood 135:912\u2013920. https:\/\/doi.org\/10.1182\/blood.2019003399","journal-title":"Blood"},{"key":"7129_CR25","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood-2022-158244","volume":"140","author":"S Buatois","year":"2022","unstructured":"Buatois S, Benkali K, Henrich A, Jaminion F, Zhang Y, Sostelly A (2022) Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMPOSER and COMMODORE 3 trials of patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 140:2918\u20132920. https:\/\/doi.org\/10.1182\/blood-2022-158244","journal-title":"Blood"},{"key":"7129_CR26","doi-asserted-by":"publisher","first-page":"e45540d8","DOI":"10.1097\/01.HS9.0000967644.45540.d8","volume":"7","author":"P Scheinberg","year":"2023","unstructured":"Scheinberg P, Cle D, Edwards J, Giai V, Hus M, Kim JS et al (2023) S183: Phase III randomized, multicenter, open-label COMMODORE 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH). Hemasphere 7:e45540d8. https:\/\/doi.org\/10.1097\/01.HS9.0000967644.45540.d8","journal-title":"Hemasphere"},{"key":"7129_CR27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/ajh.26998","volume":"98","author":"H Liu","year":"2023","unstructured":"Liu H, Xia L, Weng J, Zhang F, He C, Gao S et al (2023) Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-na\u00efve patients with PNH (COMMODORE 3): a multicenter, phase 3, single-arm study. Am J Hematol 98:1407\u20131414. https:\/\/doi.org\/10.1002\/ajh.26998","journal-title":"Am J Hematol"},{"key":"7129_CR28","doi-asserted-by":"publisher","unstructured":"Cella D, Johansson P, Ueda Y, Tomazos I, Gustovic P, Wang A et al (2021) Clinically important difference for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from International PNH Registry patient data. Blood 138:1952. https:\/\/doi.org\/10.1186\/s41687-023-00609-4","DOI":"10.1186\/s41687-023-00609-4"},{"key":"7129_CR29","unstructured":"FACIT.org (2025) FACIT-Fatigue. Functional assessment of chronic illness therapy \u2013 fatigue scale. A 13-item FACIT fatigue scale. https:\/\/www.facit.org\/measures\/FACIT-Fatigue. Accessed 6 Mar 2025"},{"key":"7129_CR30","unstructured":"National Cancer Institute (2025) Common Terminology Criteria for Adverse Events (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 6 Mar 2025"},{"key":"7129_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1198\/sbr.2009.0049","volume":"2","author":"X Yan","year":"2010","unstructured":"Yan X, Su XG (2010) Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions. Stat Biopharm Res 2:329\u2013335. https:\/\/doi.org\/10.1198\/sbr.2009.0049","journal-title":"Stat Biopharm Res"},{"key":"7129_CR32","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233\u20131243. https:\/\/doi.org\/10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"key":"7129_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA (2021) Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 15:811\u2013834. https:\/\/doi.org\/10.2147\/PPA.S303279","journal-title":"Patient Prefer Adherence"},{"key":"7129_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","volume":"8","author":"KL Stoner","year":"2015","unstructured":"Stoner KL, Harder H, Fallowfield LJ, Jenkins VA (2015) Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient 8:145\u2013153. https:\/\/doi.org\/10.1007\/s40271-014-0075-y","journal-title":"Patient"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07129-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:51Z","timestamp":1789465371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07129-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7129"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07129-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The COMMODORE 2 study complied with the ethical standards of the responsible committee on human experimentation and with the Declaration of Helsinki of 1975, revised in 2013. Approval was obtained from the institutional review board of each participating site.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jane Shi, Dayu Shi, Zilu Zhang, and Anita Appius are employees of Roche. All other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"385"}}